Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises Arginetix on Merger and Series A Financing

June 17, 2010

WASHINGTON, DC, June 17, 2010 — Arginetix, Inc. and Immune Control Inc. today announced their merger to form Corridor Pharmaceuticals, Inc., which will develop novel treatments for vascular diseases with an initial focus on pulmonary arterial hypertension (PAH). Corridor, which will be based in Baltimore, Maryland, will develop treatments based on the first-in-class arginase inhibition platform developed by Arginetix, and Immune Control’s serotonin antagonist technology. Covington & Burling LLP represented Arginetix on the merger transaction.

In conjunction with the merger, Covington also advised Corridor Pharmaceuticals on a $15 million Series A financing with all major investors of both predecessor companies. Proceeds from the financing will be used to advance C-122, Corridor’s lead candidate for PAH, into clinical development, and develop new drug candidates derived from both the Company’s arginase and serotonin platforms.

The Washington-based Covington corporate team was led by partner Doug Gibson, with associates Heather Davis and Amalia Fenton*. Also advising on tax and employee benefits aspects of the transaction were partners Robert Heller (based on New York) and Michael Francese (based in Washington).

*Admitted to the Maryland bar; not admitted to practice in Washington.

Share this article: